Overview
To evaluate the efficacy and safety of Romiplostim N01 for platelet recovery after umbilical cord blood transplantation (UCBT) in patients with hematological malignancies.
Description
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is an important means of curing a wide range of hematologic diseases, and good hematopoietic and immune reconstitution after transplantation is one of the most important factors determining the success of the transplantation.Persistent thrombocytopenia after Allo-HSCT is one of the common post-transplantation complications.This is an investigator-initiated, single-center, single-arm, Phase II clinical trial to evaluate the efficacy and safety of Romiplostim N01 for platelet recovery after UCBT in patients with hematologic tumors. The study was conducted in patients ≥18 years of age with a diagnosis of hematological neoplasia who underwent UCBT. Subjects will be screened and receive roprostin N01 from +1 to +28 days after UCBT after signing an informed consent form, and the study will focus on the cumulative PLT implantation rate at 28 days after transplantation as the primary efficacy measure. The study is planned to enroll 34 patients.
Eligibility
Inclusion Criteria:
- Age ≥12 years old, male or female;
- Patients diagnosed with hematological malignancies and undergoing UCBT;
- ECOG score ≤2;
- Voluntary participation in this clinical trial, patients fully understand the trial content and sign the informed consent
Exclusion Criteria:
- Pregnant or lactating women；
- Known allergy to Romiplostim N01;
- A history of severe thrombotic events or known risk factors for thrombosis or active thromboembolism requiring anticoagulation;
- A history of platelet dysfunction or bleeding prone disease or severe bleeding (requiring more than 2 units of red blood cell infusion or a hematocrit drop of ≥10%) within 7 days prior to screening;
- Chronic active hepatitis B and C;
- Repeat or multiple transplantation or multiple organ transplantation;
- HIV positive, EBV-DNA positive, CMV-DNA positive;
- Have severe infection or complicated with serious heart, liver, lung, kidney, neurological or metabolic diseases;
- A serious adverse event (Level 4 or 5) as defined by the Standard General Terminology for Adverse Events Version 4.0 occurred during the pre-treatment period;
- Participants participate in another clinical study with any exploratory drug or device within 30 days prior to baseline visit; Observational studies are allowed;
- Subjects with cognitive impairment or uncontrolled mental illness;
- Subjects and/or authorized family members to refuse treatment with Romiplostim N01;
- Those who are judged by the researchers as not suitable for inclusion (such as accompanying medical history, which may affect the safety of the subjects or it is estimated that the treatment cannot be adhered to due to financial problems).